Shares of Dermira Inc. (NASDAQ:DERM) climbed 82.2 percent to $12.61 on Monday after new data from a midstage study of its anti-IL-13 candidate, lebrikizumab (lebri), in atopic dermatitis (AD) showed a monthly dose of the drug performing roughly in line with Regeneron Pharmaceuticals Inc.'s blockbuster, Dupixent (dupilumab), which is dosed every other week. Though no head-to-head test with Dupixent was included in Dermira's phase IIb study, three different doses of lebri outperformed a placebo on a standard measure of eczema severity, showing efficacy that analysts said nearly matched Regeneron's drug.